ACT for COPD in India: Regenerative Support for Chronic Lung Disease | ALIV

Medically Reviewed by Dr. Sunita Tandulwadkar | Written by ALIV

Chronic Obstructive Pulmonary Disease (COPD) — the progressive airflow obstruction produced by emphysema and chronic bronchitis, most commonly from cigarette smoking — affects an estimated 55 million Indians and is the third most common cause of death globally. Standard management (bronchodilators, inhaled corticosteroids, pulmonary rehabilitation) manages symptoms effectively in early to moderate disease but slows rather than stops progressive lung function decline. For COPD patients who have optimised inhaler therapy and pulmonary rehabilitation but continue to experience progressive breathlessness and functional limitation, ALIV's ACT programme offers additional paracrine anti-inflammatory and regenerative support for the pulmonary tissue environment.

The ACT Mechanism in COPD

COPD is characterised by: chronic pulmonary inflammation driven by neutrophil and macrophage infiltration; progressive alveolar wall destruction (emphysema) driven by inflammatory protease activity (particularly elastase); small airway fibrosis and remodelling; and systemic inflammatory burden that compounds fatigue and cardiovascular comorbidity. MSC-derived anti-inflammatory paracrine signals (IL-10, TGF-β, PGE2) suppress the chronic neutrophilic and macrophage-driven pulmonary inflammation that drives alveolar destruction. VEGF supports pulmonary vascular repair and may support limited alveolar regeneration in the emphysematous lung — though the latter is a more speculative benefit given the limited regenerative capacity of mature alveolar epithelium. The systemic anti-inflammatory effect of ACT also addresses the extrapulmonary inflammatory burden that contributes to COPD-related fatigue, cardiovascular risk, and sarcopenia. See the full ACT framework: what is ACT.

Patient Selection and Staging

ACT for COPD at ALIV is most appropriate for patients with GOLD stage II–III COPD (moderate to severe, FEV1 30–79% predicted) who are on optimised inhaler therapy, have completed or are enrolled in pulmonary rehabilitation, and are non-smoking (or have achieved sustained smoking cessation). Continued active smoking is a contraindication to ACT — the ongoing oxidative and inflammatory injury from cigarette smoke directly counteracts the anti-inflammatory paracrine support and makes meaningful ACT response essentially unachievable. Very severe COPD (GOLD stage IV, FEV1 below 30%) with significant hypoxaemia is assessed individually for procedural safety and likely benefit-to-risk balance.

Can ACT reverse emphysema?

No — emphysema involves the destruction of alveolar walls, the gas-exchange structures of the lung. Destroyed alveoli do not regenerate in adults with current clinical interventions, including ACT. What ACT can support is stabilisation of further emphysema progression by reducing the inflammatory environment driving ongoing alveolar destruction; improvement in airway inflammation that contributes to breathlessness; and improved systemic inflammatory and energy status that enhances exercise tolerance and quality of life. The clinical goal is meaningful functional improvement in what remains — not restoration of what has been destroyed.

Will I be able to reduce my inhalers if ACT works?

Inhaler therapy should not be reduced based on perceived ACT benefit without explicit pulmonologist assessment. ACT may support better inhaler efficacy and reduce the frequency of acute exacerbations — but it does not replace the bronchodilatory and anti-inflammatory function of correctly prescribed inhaled therapy. Any medication changes should be made by the treating pulmonologist based on objective spirometry and clinical assessment.

Medically Reviewed by Dr. Sunita Tandulwadkar. This article is for informational purposes only and does not constitute medical advice. Therapies offered by ALIV are proprietary, experimental protocols and results vary by individual.